Recent developments of interest in cardiovascular medicine
The KardiaMobile device yielded more heart rhythm diagnoses and was faster and cheaper than conventional care, according to a U.K. study finding a 56% diagnosis rate in an average of 9.5 days compared with 10% over 43 days. (MobiHealthNews)
Is the FDA cheerleading for Apple's ECG tech? (Politico)
Transitioning to high-sensitivity troponin (hs-TnT) testing: It's complicated. (Journal of the American College of Cardiology)
A ready-to-use formulation of the platelet aggregation inhibitor eptifibatide (Integrilin) was approved for treating acute coronary syndrome, Baxter International announced.
A prison salt trial might not be ethical as proposed, a viewpoint piece argued in the Annals of Internal Medicine.
The first patient in a hepatitis C-positive donor heart transplant study is profiled in Cardiovascular Business.
One lot of American Health Packaging's valsartan
(obtained from Aurobindo Pharma) and an additional 114 lots of Torrent Pharmaceuticals' losartan and losartan/hydrochlorothiazide
(obtained from Hetero Labs) are under recall due to contamination with a probable carcinogen.
Two deaths prompted the FDA to issue an alert about software updates for Zoll's LifeVest 4000 wearable cardioverter defibrillators, reemphasizing the need to immediately contact the company for a replacement in case of an error code. (Mass Device)
The Resting Full-Cycle Ratio (RFR) diagnostic test was cleared by the FDA to identify coronary artery stenosis severity without use of vasodilators in patients with coronary artery disease. (Medical Design & Outsourcing)
Iron deposition from hematomas "may play a critical role in initiation" of aortic valve calcification. (Journal of the American College of Cardiology)
Gestational diabetes is associated with double the risk of cardiovascular disease in subsequent years, with increased risk even for women who don't develop type 2 diabetes, researchers reported in Diabetologia.
Read the original article on Medpage Today: Kardia Better for Diagnosis; hs-TnT Transition; Prison Salt Trial